看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
% E5 w+ u2 t9 a: j f2 m4 Q3 @
7 z: w2 Q; H$ [0 r# G
+ W6 ^% V2 f G5 t! _8 s6 o) XCurrently available feasibility data for possible combination strategies.
9 g0 c& G d% b————————————————————————————————
: U; i2 o& d6 v3 b/ ^9 ? R8 d$ UCombination Feasibility according to preliminary data 3 T( u: E2 ~) e
——————————————————————————————————6 c9 j) a$ h. p+ D/ B2 Z. L5 E1 t
Bevacizumab + sorafenib Yes, reduced dose
: n1 O4 g9 c# ~ d# SBevacizumab + sunitinib† No 7 T: l1 j5 Z( \4 @9 g. |! d. H
Bevacizumab + temsirolimus Yes 5 I" ^; l7 m" H7 I, F
Bevacizumab + everolimus Yes
@5 X' p9 d/ T5 q1 ySorafenib + sunitinib ?
9 G' A" [% O0 U9 dSorafenib + temsirolimus Yes, reduced dose ! C5 C) B3 y0 @8 y, N) m, _3 n
Sorafenib + everolimus Yes, reduced dose
: W& ?& G0 ]4 W. j) CSunitinib + temsirolimus† No
; `1 M( {9 e* Q0 @Sunitinib + everolimus ? 3 j* \7 E* L( E
Temsirolimus + everolimus ?
/ o5 c! p# b& B$ D' k) ?9 }) M———————————————————— U/ S9 @* `2 n9 G9 D
†Led to US FDA warning.# z! Z3 }) R) N g1 x
?: As yet unattempted combination.
. M% m2 m4 ~( _4 M' J l) [! Z |